217 related articles for article (PubMed ID: 35047405)
1. The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation.
Abou Dalle I; Atoui A; Bazarbachi A
Front Oncol; 2021; 11():793274. PubMed ID: 35047405
[TBL] [Abstract][Full Text] [Related]
2. Treatment of AML Relapse After Allo-HCT.
Webster JA; Luznik L; Gojo I
Front Oncol; 2021; 11():812207. PubMed ID: 34976845
[TBL] [Abstract][Full Text] [Related]
3. Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Shi W; Jin W; Xia L; Hu Y
Acta Pharm Sin B; 2020 Nov; 10(11):2125-2139. PubMed ID: 32837873
[TBL] [Abstract][Full Text] [Related]
4. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
5. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!
Abou Dalle I; El Cheikh J; Bazarbachi A
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326641
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy for AML after allogeneic HCT.
Nayak RK; Chen YB
Front Oncol; 2022; 12():895771. PubMed ID: 36016625
[TBL] [Abstract][Full Text] [Related]
9. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.
Kanate AS; Pasquini MC; Hari PN; Hamadani M
World J Stem Cells; 2014 Apr; 6(2):69-81. PubMed ID: 24772235
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.
Gyurkocza B; Lazarus HM; Giralt S
Bone Marrow Transplant; 2017 Aug; 52(8):1083-1090. PubMed ID: 28244979
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.
Bazarbachi A; Schmid C; Labopin M; Beelen D; Wolfgang Blau I; Potter V; Niittyvuopio R; Socié G; Blaise D; Sanz J; Ciceri F; Abou Dalle I; Spyridonidis A; Bug G; Esteve J; Savani BN; Nagler A; Mohty M
Clin Cancer Res; 2020 Dec; 26(24):6475-6482. PubMed ID: 32988970
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M
Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.
Ertz-Archambault N; Kosiorek H; Slack JL; Lonzo ML; Greipp PT; Khera N; Kelemen K
Biol Blood Marrow Transplant; 2017 May; 23(5):782-789. PubMed ID: 28189903
[TBL] [Abstract][Full Text] [Related]
16. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
17. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
18. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents.
Martino M; Fedele R; Moscato T; Ronco F
Curr Cancer Drug Targets; 2013 Jul; 13(6):661-9. PubMed ID: 23713435
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
20. Metabolic instruction of the graft-versus-leukemia immunity.
Burk AC; Apostolova P
Front Immunol; 2024; 15():1347492. PubMed ID: 38500877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]